176-177 / 2001
1999 2016 ; the evolution !
-
•
Ideas progressively changed …
•
Risk groups ; should brachytherapy as
monotherapy be reserved to low-risk
patients ?
•
What about age ?
•
What about the biopsies ?( Percentage of
involved samples, microfoci, bilaterality …)
•
What about median lobes and obstructive
syndroms ?
•
Which role for MRI ?